These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9628276)

  • 1. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM.
    Kong MF; Stubbs TA; King P; Macdonald IA; Lambourne JE; Blackshaw PE; Perkins AC; Tattersall RB
    Diabetologia; 1998 May; 41(5):577-83. PubMed ID: 9628276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM.
    Kong MF; King P; Macdonald IA; Stubbs TA; Perkins AC; Blackshaw PE; Moyses C; Tattersall RB
    Diabetologia; 1997 Jan; 40(1):82-8. PubMed ID: 9028722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
    Rodriguez LM; Mason KJ; Haymond MW; Heptulla RA
    Pediatr Res; 2007 Dec; 62(6):746-9. PubMed ID: 17957149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects.
    Chapman I; Parker B; Doran S; Feinle-Bisset C; Wishart J; Lush CW; Chen K; Lacerte C; Burns C; McKay R; Weyer C; Horowitz M
    Obesity (Silver Spring); 2007 May; 15(5):1179-86. PubMed ID: 17495194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
    Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.
    Chase HP; Lutz K; Pencek R; Zhang B; Porter L
    J Pediatr; 2009 Sep; 155(3):369-73. PubMed ID: 19464026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus.
    Vella A; Lee JS; Camilleri M; Szarka LA; Burton DD; Zinsmeister AR; Rizza RA; Klein PD
    Neurogastroenterol Motil; 2002 Apr; 14(2):123-31. PubMed ID: 11975712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.
    Kolterman OG; Schwartz S; Corder C; Levy B; Klaff L; Peterson J; Gottlieb A
    Diabetologia; 1996 Apr; 39(4):492-9. PubMed ID: 8778001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of euglycaemic hyperinsulinaemia on gastric emptying and gastrointestinal hormone responses in normal subjects.
    Kong MF; King P; Macdonald IA; Blackshaw PE; Perkins AC; Armstrong E; Buchanan KD; Tattersall RB
    Diabetologia; 1998 Apr; 41(4):474-81. PubMed ID: 9562353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
    Singh-Franco D; Robles G; Gazze D
    Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
    Fineman M; Weyer C; Maggs DG; Strobel S; Kolterman OG
    Horm Metab Res; 2002 Sep; 34(9):504-8. PubMed ID: 12384827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
    Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
    Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?
    Asmar M; Bache M; Knop FK; Madsbad S; Holst JJ
    J Clin Endocrinol Metab; 2010 May; 95(5):2367-75. PubMed ID: 20194711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of an oral drug (acetaminophen) administered at various times relative to subcutaneous injection of pramlintide in subjects with type 2 diabetes.
    Kellmeyer TA; Kesty NC; Wang Y; Frias JP; Fineman MS
    J Clin Pharmacol; 2007 Jul; 47(7):798-805. PubMed ID: 17463219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
    Ryan GJ; Jobe LJ; Martin R
    Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes.
    Amiel SA; Heller SR; Macdonald IA; Schwartz SL; Klaff LJ; Ruggles JA; Weyer C; Kolterman OG; Maggs DG
    Diabetes Obes Metab; 2005 Sep; 7(5):504-16. PubMed ID: 16050943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition.
    Samsom M; Szarka LA; Camilleri M; Vella A; Zinsmeister AR; Rizza RA
    Am J Physiol Gastrointest Liver Physiol; 2000 Jun; 278(6):G946-51. PubMed ID: 10859225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans.
    Woerle HJ; Albrecht M; Linke R; Zschau S; Neumann C; Nicolaus M; Gerich J; Göke B; Schirra J
    Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E103-9. PubMed ID: 17971511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial.
    Thompson RG; Peterson J; Gottlieb A; Mullane J
    Diabetes; 1997 Apr; 46(4):632-6. PubMed ID: 9075803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patients.
    King AB
    Diabetes Technol Ther; 2010 Feb; 12(2):105-8. PubMed ID: 20105039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.